Clinical Trial Update: The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial update for brexpiprazole as adjunctive therapy in major depressive disorder has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• brexpiprazole (brexpiprazole)

Snippet

Sponsor: Otsuka Beijing Research Institute | Conditions: Major Depressive Disorder | Phase 3 | Status: TERMINATED